HK Stock Market Move | INNOCARE (09969) rises by over 5%, new generation pan-TRK inhibitor new drug application accepted

INNOCARE (09969) rose more than 5%, reaching a 5.44% increase at the time of publication, trading at HK$8.72 with a trading volume of HK$19.4238 million. On the news front, on April 16, INNOCARE announced that the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has accepted the new drug application (NDA) for the next-generation pan-TRK inhibitor Zurletrectinib (ICP-723) for the treatment of advanced solid tumors in adults and adolescents (aged 12 years and older, <18 years) carrying NTRK fusion genes. Zurletrectinib is an internally developed pan-TRK inhibitor by INNOCARE, which can effectively inhibit TRKA, TRKB, TRKC and also overcome acquired resistance mutations in TRKA such as G595R and G667C, thus overcoming the acquired resistance seen with first-generation TRK inhibitors.